|
| 33562646 | Metformin and Androgen Receptor-Axis-Targeted (ARAT) Agents Induce Two PARP-1-Dependent Cell Death Pathways in Androgen-Sensitive Human Prostate Cancer Cells. | Cancers (Basel) | 2021 |
| 27286290 | Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1. | J Vis Exp | 2016 |
| 27590344 | Death-associated Protein Kinase-1 Expression and Autophagy in Chronic Lymphocytic Leukemia Are Dependent on Activating Transcription Factor-6 and CCAAT/Enhancer-binding Protein-β. | J Biol Chem | 2016 |
| 25586604 | Concomitant bone marrow involvement by plasma cell myeloma and primary myelodysplastic syndrome with biclonal complex chromosome anomalies. | Leuk Lymphoma | 2015 |
| 25615818 | Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells. | Biochim Biophys Acta | 2015 |
| 23150485 | Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. | Mol Pharmacol | 2013 |
| 24189494 | Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steroidogenic factor-1. | Biochim Biophys Acta | 2013 |
| 23403629 | Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. | Clin Cancer Res | 2013 |
| 23065516 | Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells. | Haematologica | 2013 |
| 22098950 | Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. | Chin J Cancer | 2012 |
| 22248732 | Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. | Biochem Pharmacol | 2012 |
| 21220496 | Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. | Mol Cancer Ther | 2011 |
| 21553329 | Creative solution for implementation of experiential, competency-based palliative care training for internal medicine residents. | J Cancer Educ | 2011 |
| 21718815 | Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine. | Biochim Biophys Acta | 2011 |
| 19949928 | Impact of breast cancer resistance protein on cancer treatment outcomes. | Methods Mol Biol | 2010 |
| 20804740 | A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. | Biochem Pharmacol | 2010 |
| 20510678 | Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors. | Biochem Pharmacol | 2010 |
| 20460431 | Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2). | Mol Pharmacol | 2010 |
| 20145614 | Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. | Br J Cancer | 2010 |
| 20419431 | Methods to evaluate transporter activity in cancer. | Methods Mol Biol | 2010 |
| 19223502 | Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. | Clin Cancer Res | 2009 |
| 19509267 | Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. | Mol Cancer Ther | 2009 |
| 18042733 | Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. | Mol Pharmacol | 2008 |
| 18186545 | Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses. | Stat Med | 2008 |
| 18056989 | The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. | J Biol Chem | 2008 |
| 17187253 | Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL. | Cancer Chemother Pharmacol | 2007 |
| 17475205 | Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells. | Arch Biochem Biophys | 2007 |
| 16543472 | Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. | Blood | 2006 |
| 16770788 | Thapsigargin resistance in human prostate cancer cells. | Cancer | 2006 |
| 16707421 | Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. | Cancer Res | 2006 |
| 16944951 | Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cells. | J Proteome Res | 2006 |
| 16404634 | Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. | Cancer Chemother Pharmacol | 2006 |
| 15661261 | A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. | Leuk Res | 2005 |
| 16238509 | Long-term evaluation of required coursework in palliative and end-of-life care for medical students. | J Palliat Med | 2005 |
| 16273296 | Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. | Int J Mol Med | 2005 |
| 16322302 | Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. | Clin Cancer Res | 2005 |
| 16083366 | Message for mid-term, 2005. | J Cancer Educ | 2005 |
| 15994225 | The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. | Proc Natl Acad Sci U S A | 2005 |
| 16026644 | Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. | Neoplasia | 2005 |
| 15580504 | Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors. | Cancer Chemother Pharmacol | 2005 |
| 14618629 | Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. | Int J Cancer | 2004 |
| 15634651 | Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. | Mol Cancer Ther | 2004 |
| 15521915 | Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. | Br J Haematol | 2004 |
| 15623606 | Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. | Clin Cancer Res | 2004 |
| 15208643 | Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function. | Leukemia | 2004 |
| 15203030 | Liquid chromatography method for the quantitation of the breast cancer resistance protein ABCG2 inhibitor fumitremorgin C and its chemical analogues in mouse plasma and tissues. | J Chromatogr B Analyt Technol Biomed Life Sci | 2004 |
| 15494300 | Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. | Best Pract Res Clin Haematol | 2004 |
| 15456662 | Development of required postgraduate palliative care training for internal medicine residents and medical oncology fellows. | J Cancer Educ | 2004 |
| 15324691 | Mining our ABCs: pharmacogenomic approach for evaluating transporter function in cancer drug resistance. | Cancer Cell | 2004 |
| 14973083 | Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. | Cancer Res | 2004 |